Cyclodextrin-erythromycin complexes as a drug delivery device for orthopedic application

Area of Science:

• Biomedical Engineering
• Materials Science
• Pharmacology

Background:

• Erythromycin, an antibiotic, exhibits anti-inflammatory properties and inhibits osteoclast formation.
• Orthopedic inflammation presents a challenge for sustained therapeutic delivery.
• Cyclodextrin complexation offers a potential strategy for drug delivery.

Purpose of the Study:

• To develop and characterize a cyclodextrin-erythromycin (CD-EM) complex.
• To evaluate the sustained release and anti-inflammatory potential of the CD-EM complex.
• To assess the safety and efficacy of the CD-EM complex in relevant cell models.

Main Methods:

• Erythromycin was complexed with β-cyclodextrin using kneading and stirring methods.
• Physicochemical properties of the CD-EM complex were analyzed.
• Cytotoxicity, cell differentiation, and osteoclast formation were evaluated in MC3T3 and RAW 264.7 cells.

Main Results:

• A non-host-guest packing complex of erythromycin and cyclodextrin was formed.
• The CD-EM complex demonstrated enhanced stability and prolonged bactericidal activity compared to free erythromycin.
• The CD-EM complex was noncytotoxic, inhibited osteoclast formation, and did not impede osteoblast viability or differentiation.

Conclusions:

• The CD-EM complex offers improved stability and sustained release of erythromycin.
• This complex shows potential for localized and sustained treatment of orthopedic inflammation.
• The findings support the use of CD-EM for managing periprosthetic inflammation.